Literature DB >> 18090430

Primary progressive aphasia: a 25-year retrospective.

M-Marsel Mesulam1.   

Abstract

The diagnosis of primary progressive aphasia (PPA) is made in any patient in whom a language impairment (aphasia), caused by a neurodegenerative disease (progressive), constitutes the most salient aspect of the clinical picture (primary). The language impairment can be fluent or nonfluent and may or may not interfere with word comprehension. Memory for recent events is relatively preserved although memory scores obtained in verbally mediated tests may be abnormal. Lesser changes in behavior and object recognition may be present but are not the leading factors that bring the patient to medical attention. This selective clinical pattern is most conspicuous in the initial stages of the disease. Progressive nonfluent aphasia and some types of semantic dementia can be considered subtypes of PPA. Initially brought to the attention of contemporary literature 25 years ago, PPA has recently witnessed substantial progress related to its neurolinguistic features, neuroanatomy, imaging, neuropathology, genetics, and risk factors.

Entities:  

Mesh:

Year:  2007        PMID: 18090430     DOI: 10.1097/WAD.0b013e31815bf7e1

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  25 in total

1.  Distinct neural substrates for semantic knowledge and naming in the temporoparietal network.

Authors:  Benno Gesierich; Jorge Jovicich; Marianna Riello; Michela Adriani; Alessia Monti; Valentina Brentari; Simon D Robinson; Stephen M Wilson; Scott L Fairhall; Maria Luisa Gorno-Tempini
Journal:  Cereb Cortex       Date:  2011-11-02       Impact factor: 5.357

2.  Neuropsychiatric symptoms in primary progressive aphasia: phenomenology, pathophysiology, and approach to assessment and treatment.

Authors:  Mandana Modirrousta; Bruce H Price; Bradford C Dickerson
Journal:  Neurodegener Dis Manag       Date:  2013-04-01

3.  The arcuate fasciculus and the disconnection theme in language and aphasia: history and current state.

Authors:  Marco Catani; Marsel Mesulam
Journal:  Cortex       Date:  2008-05-23       Impact factor: 4.027

4.  Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism.

Authors:  Edward Tobinick
Journal:  Medscape J Med       Date:  2008-06-10

5.  Neuropsychiatric aspects of primary progressive aphasia.

Authors:  Yasaman Fatemi; Bradley F Boeve; Joseph Duffy; Ronald C Petersen; David S Knopman; Vladimir Cejka; Glenn E Smith; Yonas E Geda
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2011       Impact factor: 2.198

6.  Augmented input reveals word deafness in a man with frontotemporal dementia.

Authors:  Chris Gibbons; Barry Oken; Melanie Fried-Oken
Journal:  Behav Neurol       Date:  2012       Impact factor: 3.342

7.  Slowed articulation rate is a sensitive diagnostic marker for identifying non-fluent primary progressive aphasia.

Authors:  Claire Cordella; Bradford C Dickerson; Megan Quimby; Yana Yunusova; Jordan R Green
Journal:  Aphasiology       Date:  2016-07-21       Impact factor: 2.773

8.  Dissociations Between Fluency And Agrammatism In Primary Progressive Aphasia.

Authors:  Cynthia K Thompson; Soojin Cho; Chien-Ju Hsu; Christina Wieneke; Alfred Rademaker; Bing Bing Weitner; M-Marsel Mesulam; Sandra Weintraub
Journal:  Aphasiology       Date:  2012       Impact factor: 2.773

9.  Phonological facilitation of object naming in agrammatic and logopenic primary progressive aphasia (PPA).

Authors:  Jennifer E Mack; Soojin Cho-Reyes; James D Kloet; Sandra Weintraub; M-Marsel Mesulam; Cynthia K Thompson
Journal:  Cogn Neuropsychol       Date:  2013-09-27       Impact factor: 2.468

10.  Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study.

Authors:  Peter K Panegyres; Jeffrey M Rogers; Michael McCarthy; Andrew Campbell; Jing Shan Wu
Journal:  BMC Neurol       Date:  2009-08-12       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.